MedPath

Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS)

Not Applicable
Conditions
Stable Angina
Angina
Unstable Angina
Coronary Artery Disease
Interventions
Device: Predilatation with OPN NC balloon catheter.
Device: Predilatation with standard compliant balloon.
Device: Absorb BVS implantation.
Procedure: Treated segment visualization by OCT.
Other: Clinical FU at 12 months.
Registration Number
NCT02468960
Lead Sponsor
SIS Medical AG
Brief Summary

Study aim : To compare a novel strategy of lesion preparation with noncompliant balloons before implantation of BVS (Bioresorbable Vascular Scaffold).

Hypothesis: Predilatation with non-compliant balloons could facilitate optimal deployment of BVS. By achieving good scaffold apposition a need for post-dilatation could be significantly reduced. This is expected to result in better short- and long-term outcomes.

Detailed Description

Study design:

Following pre-dilatation a BVS will be implanted and optical coherence tomography (OCT) will be performed in all patients. After OCT post-dilatation with non-compliant balloons might be performed if this is considered necessary by the treating interventionist. Final OCT will be performed in all patients. 1:1 Randomization of two strategies before the implantation of bioresorbable scaffolds:

* OPN strategy (study group): pre-dilatation with OPN NC ® Super High Pressure PTCA (Percutaneous Transluminal Coronary Angioplasty) balloons

* standard strategy (control group): pre-dilatation with a standard (compliant) balloon

Enrolment:

Randomization of 50 patients

* 25 in the OPN strategy (study group)

* 25 in the standard strategy (control group)

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Age > 18 years.
  • Able and willing to give informed consent.
  • Willing to comply with specified follow-up evaluations.
  • Clinical manifestation of coronary artery disease: stable angina, unstable angina or non-ST-elevation myocardial infarction.
  • De novo lesion.
  • Angiographic diameter stenosis > 70 % and/or fractional flow reserve <0.80.
  • Vessel diameter between 2.5 and 4.0 mm.
  • One- or two vessel disease (defined as diameter stenosis > 70 % in vessels with a diameter > 2.5 mm).
  • Up to two lesions in one or two vessels can be treated
Exclusion Criteria
  • Patient characteristics

    • Pregnant or nursing patient or planned pregnancy in the period up to 1 year following the index procedure.
    • Patient with contraindication for 12 months of dual antiplatelet therapy.
    • ST-elevation myocardial infarction.
    • Any contraindication to the implantation of BVS. Lesion characteristics
    • Visible thrombus in coronary angiography
    • Chronic total occlusion

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
OPN strategy (study group)Absorb BVS implantation.Interventions planned in this arm are as follows: * Predilatation with OPN NC balloon catheter. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
OPN strategy (study group)Predilatation with OPN NC balloon catheter.Interventions planned in this arm are as follows: * Predilatation with OPN NC balloon catheter. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
Standard strategy (control group)Absorb BVS implantation.Interventions planned in this arm are as follows: * Predilatation with standard compliant balloon. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
OPN strategy (study group)Treated segment visualization by OCT.Interventions planned in this arm are as follows: * Predilatation with OPN NC balloon catheter. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
Standard strategy (control group)Treated segment visualization by OCT.Interventions planned in this arm are as follows: * Predilatation with standard compliant balloon. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
Standard strategy (control group)Clinical FU at 12 months.Interventions planned in this arm are as follows: * Predilatation with standard compliant balloon. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
OPN strategy (study group)Clinical FU at 12 months.Interventions planned in this arm are as follows: * Predilatation with OPN NC balloon catheter. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
Standard strategy (control group)Predilatation with standard compliant balloon.Interventions planned in this arm are as follows: * Predilatation with standard compliant balloon. * Absorb BVS implantation. * Treated segment visualization by OCT. * Clinical FU at 12 months.
Primary Outcome Measures
NameTimeMethod
Scaffold apposition ratio in both groups (ratio of malapossition stents to total stents per cross-sectionParticipants will be followed for the duration of index procedure, an expected average of 1 hour.

Outcome will be analyzed by independent Angio CoreLab based on data recorded during index PCI procedure.

Secondary Outcome Measures
NameTimeMethod
Need for post-dilatation after implantation of the scaffoldParticipants will be followed for the duration of index procedure, an expected average of 1 hour.
Procedural success defined as successful delivery of the scaffoldParticipants will be followed for the duration of index procedure, an expected average of 1 hour.
Scaffold apposition after post-dilatationParticipants will be followed for the duration of index procedure, an expected average of 1 hour.

Outcome will be analyzed by independent Angio CoreLab based on data recorded during index PCI procedure.

Frequency and total number of periprocedural complications: dissection, slow- or no flow, dissection requiring additional stent implantation,Participants will be followed for the duration of index procedure, an expected average of 1 hour.

Trial Locations

Locations (1)

Luzernen Kantonsspital, Spitalstrasse 16

🇨🇭

Luzern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath